Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.

Authors:
  • ARA J Reyntjens
    A J Reyntjens
  • CNC J Niemegeers
    C J Niemegeers
  • JNJ M Van Nueten
    J M Van Nueten
  • PLP Laduron
    P Laduron
  • JHJ Heykants
    J Heykants
  • KSK H Schellekens
    K H Schellekens
  • RMR Marsboom
    R Marsboom
  • AJA Jageneau
    A Jageneau
  • ABA Broekaert
    A Broekaert
  • PJP A Janssen
    P A Janssen

  • 1 January 1978
    • journal article
    • Vol. 28  (7) , 1194-6
    • PMID:582708
Abstract
The new potent anti-nauseant 5-chloro-1-(1p[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-propyl]-4-piperidinyl)-1.3-dihydro-2H-benzimidazol-2-one (domperidone), which in contrast to available anti-emetics does not provoke extrapyramidal or adrenolytic adverse effects, also enhances gastric emptying motility. Controlled clinical trials have confirmed its prokinetic effects on the stomach and its lack of side-effects, even at high doses. This anti-nauseant appears to be a safe and effective treatment for patients, both adults and children, with dyspepsia or vomiting.